Objective Evaluation of Physical Function in Patients with Advanced Lung Cancer: A Preliminary Report

Montoya, Maria E.; Fossella, Frank V.; Palmer, J. Lynn; Kaur, Guddi; Pace, Ellen; Yadav, Rajesh; Simmonds, Maureen J.; Gillis, Theresa A.; Bruera, Éduardo

doi:10.1089/jpm.2006.9.309

Cited by 14 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, physical fitness for treatment is determined largely by the PS score. This score is imperfect as it is subjective, with reports of interobserver variability,87 and there is only a modest correlation between PS and observed physical performance 88. Interclinician PS discordance has led to a lower percentage of PS 0 and 1 patients appearing to get chemotherapy,89 and has led to a call for objective evaluation of physical functioning 90.…”

Section: Discussionmentioning

confidence: 99%

The assessment and impact of sarcopenia in lung cancer: a systematic literature review

et al. 2014

View full text Add to dashboard Cite

ObjectivesThere is growing awareness of the relationship between sarcopenia (loss of muscle mass and function), and outcomes in cancer, making it a potential target for future therapies. In order to inform future research and practice, we undertook a systematic review of factors associated with loss of muscle mass, and the relationship between muscle function and muscle mass in lung cancer, a common condition associated with poor outcomes.DesignWe conducted a computerised systematic literature search on five databases. Studies were included if they explored muscle mass as an outcome measure in patients with lung cancer, and were published in English.SettingSecondary care.ParticipantsPatients with lung cancer.Primary outcomeFactors associated with loss of muscle mass and muscle function, or sarcopenia, and the clinical impact thereof in patients with lung cancer.ResultsWe reviewed 5726 citations, and 35 articles were selected for analysis. Sarcopenia, as defined by reduced muscle mass alone, was found to be very prevalent in patients with lung cancer, regardless of body mass index, and where present was associated with poorer functional status and overall survival. There were diverse studies exploring molecular and metabolic factors in the development of loss of muscle mass; however, the precise mechanisms that contribute to sarcopenia and cachexia remain uncertain. The effect of nutritional supplements and ATP infusions on muscle mass showed conflicting results. There are very limited data on the correlation between degree of sarcopenia and muscle function, which has a non-linear relationship in older non-cancer populations.ConclusionsLoss of muscle mass is a significant contributor to morbidity in patients with lung cancer. Loss of muscle mass and function may predate clinically overt cachexia, underlining the importance of evaluating sarcopenia, rather than weight loss alone. Understanding this relationship and its associated factors will provide opportunities for focused intervention to improve clinical outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

The assessment and impact of sarcopenia in lung cancer: a systematic literature review

et al. 2014

View full text Add to dashboard Cite

show abstract

“…6 Several investigators have used these physical performance tests to describe treatment and temporal changes in the physical and functional capacity of patients with specific oncology diagnoses, including lung and breast cancer patients as well as oncology patients receiving palliative care. [7][8][9][10] However, the outcomes reported in these studies vary substantially from the normative values reported by Simmonds. 6 Although these studies demonstrate the clinical utility of this battery of tests, the variance in normative values for these tests that exists across these studies suggests the need to develop reference values based on specific cancer diagnoses.…”

Section: Introductionmentioning

confidence: 59%

“…[7][8][9][10] Specifically, Basen-Engquist et al 8 reported that breast cancer survivors were fitter than a heterogeneous oncology population, as did Montoya et al 7 for advanced lung cancer patients. Given the complexities of various cancers and the wide variety of adverse effects arising from cancer treatments, differences in functional performance measures should be anticipated.…”

Section: Groupmentioning

confidence: 98%

“…Elapsed time was provided to the patient at intervals of 1 min, and testers limited other verbal encouragement to 'you are doing well' or 'keep up the good work'. 7 The tester followed the patient during the test for safety reasons and pushed a surveyor's wheel to record distance covered by the patient. Results of this test are reported in meters.…”

Section: Functional Assessmentmentioning

confidence: 99%

See 1 more Smart Citation

Functional performance status of hematopoietic SCT recipients in the sub-acute phase of recovery

Morris

Brueilly

Scheetz

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

This study assessed the functional capacity of sub-acute SCT recipients using validated physical performance tests, including 6-min walk distance, repeated sit-to-stand time and 50-ft walk time, and compared these outcomes with those reported for a heterogeneous oncology population. The medical records of 80 consecutive sub-acute SCT recipients not receiving corticosteroids were retrospectively reviewed for demographic, medical and anthropometric information, and outcomes for these physical performance tests administered at the time of initial physiotherapy evaluation. Measures of central tendency, 95% confidence intervals, unpaired t-tests and correlation coefficients were calculated using a SPSS statistical package. SCT recipients completed the 50-ft walk in 10.66 ± 4.43 s, repeated sit-to-stand trial in 4.16 ± 1.82 s and walked 400.2 m in 6 min. For the timed tests, SCT recipients were approximately twice as fast as a heterogeneous group of oncology patients and walked approximately 50% further in 6 min. No overlap in the 95% confidence intervals for the two groups was observed for any of the tests. These results (1) suggest that reference values describing the functional capacity of a heterogeneous oncology population underestimate the functional capacity of SCT recipients and (2) provide clinically useful reference values for assessing functional capacity of sub-acute SCT recipients referred for physiotherapy.

show abstract

“…First, we could not identify any validated score of performance status in the chart review. [23][24][25]. Therefore, we believed we had minimized our first study limitation.…”

Section: Study Limitationsmentioning

confidence: 99%

Frequency and Determining Factors of Empiric Chemotherapy Dose Reduction in Patients with Non-Small Cell Lung Cancer

Kartolo¹,

Wong²,

Cheng³

2017

IJCR

View full text Add to dashboard Cite

Objective Evaluation of Physical Function in Patients with Advanced Lung Cancer: A Preliminary Report

Cited by 14 publications

References 25 publications

The assessment and impact of sarcopenia in lung cancer: a systematic literature review

The assessment and impact of sarcopenia in lung cancer: a systematic literature review

Functional performance status of hematopoietic SCT recipients in the sub-acute phase of recovery

Frequency and Determining Factors of Empiric Chemotherapy Dose Reduction in Patients with Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About